Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Shareholder Meeting (November 2023)
17 slides from Zelira Therapeutics's shareholder meeting presentation, Nov 15, 2023
Slide 1: 2023 Annual Shareholders General Meeting
ZELIRA THERAPEUTICS For personal use only 2023 Annual Shareholders General Meeting Investor Briefing 15 November 2023 ASX: ZLD OTCQB:ZLDAF zeliratx.com
Slide 2: Disclaimer & Important Notice
DISCLAIMER & IMPORTANT NOTICE Disclaimer Future Matters For personal use only This presentation has been prepared by Zelira affairs, financial position or prospects of the Company. This presentation contains reference to certain intentions, Therapeutics Ltd ACN 103 782 378 (“Company”). It The Compan
Slide 3: Highlights 2022-2023
Highlights 2022 2023 13 Jul 22 10 Jan 23 ZENIVOL® achieves major milestone with Full repayment of $1.75M in cash and formal regulatory approval received in Germany shares received from Health House/Creso For personal use only 8 Sep 22 30 Jan 23 $400K partial repayment of loan received Zelira receive
Slide 4: Achievements Q1 FY24
Achievements- Q.1 FY24: First close of SPV funding leads to stronger cash position For personal use only First close of HOPE-SPV funding Total committed US$3.25 million investment in commitment, enabling HOPE® SPV to date the initiation of HOPE® is $11.85 million Stronger closing cash clinical trial
Slide 5: Positive Readout of topline results from Diabetic Nerve trial
For personal use only Positive Readout of topline results from Diabetic Nerve trial Zelira’s Diabetic Nerve Pain Drug Outperforms Big Pharma drug; successful clinical trial against multi-billion-dollar Lyrica® Demonstrated Safety, Tolerability, and Improved Efficacy CONFIDENTIAL UNDER TERMS OF NON-D
Slide 6: Diabetic Nerve Pain Drug ZLT-L-007 Outperforms Lyrica
Zelira’s Diabetic Nerve Pain Drug (ZLT-L-007) Outperforms Big Pharma drug; successful clinical trial against multi-billion-dollar Lyrica® Demonstrated Safety, Tolerability, and Improved Efficacy For personal use only Objective of the study Topline Results Market Potential • Comparing Zelira’s patent
Slide 7: Unique Rapid Commercialisation Strategy
Zelira’s Unique Rapid Commercialisation Strategy- Key to success For personal use only Launch Learn Develop Generate proprietary formulations Collect real-world patient data Patient data informs and de-risks design of clinical trial Launch products in global markets Refine product to meet patient ne
Slide 8: HOPE - Real World Evidence
HOPE®- Real World Evidence For personal use only Autism patients report HOPE® Grows For Autism improvement in symptoms video showing a before and quality of life with and after experience on Zelira Therapeutics’ HOPE® cannabinoid medication Launch & Learn Video of Australian Autism Spectrum Disorder
Slide 9: FDA trials for HOPE represent final stage of strategy
FDA trials for HOPE® 1 represents third and final stage of Launch, Learn, Develop strategy for validation and commercialisation For personal use only HOPE® launched in Over 9 Million doses All sales in the US are Proprietary HOPE® 1 product Pennsylvania in 2020 of HOPE® dispensed out of pocket payme
Slide 10: Key Highlights: Progressing HOPE 1 into US FDA Clinical Trials
MAJOR Key Highlights Of The Announcement Progressing 2023 HOPE® 1 into US FDA Clinical Trials MILESTONE For personal use only HOPE® special US-based Cantheon Zelira to raise up to Specialist Execution purpose vehicle Capital LLC, global an additional circa cannabinoid of definitive (SPV) established
Slide 11: Portfolio of Clinically Validated Assets
ZELIRA’S PORTFOLIO OF CLINICALLY VALIDATED ASSETS For personal use only Autism Insomnia Oral Care Dermatology Neuropathy Platform PRODUCT HOPE® ZENIVOL® SprinJene RAF FIVE™ ITURA™ Technology CBD ZYRADI™ (EDCDM) & Novel Encapsulation 2020 2020 2021 2021 2021 2022 DATE OF LAUNCH CURRENT MARKETS Via Bu
Slide 12: Zelira Patent Portfolio
Zelira Patent Portfolio 58 A significant distinction of the Zelira strategy patents granted US Patent Office is our investment in patent protection granted the For personal use only HOPE® patent Patent Family Accepted, Granted, Accepted, Granted, Certified or Validated Certified or Validated in Apri
Slide 13: Zelira Catalyst for Growth: Advancing Product Development
ZELIRA CATALYST FOR GROWTH For personal use only Advancing Product Development Positive progress with the development work to change Zenivol® format to a capsule formulation powered by Zyraydi™ technology. CONFIDENTIAL UNDER TERMS OF NON-DISCLOSURE AGREEMENT
Slide 14: Advancing Clinical Validation of Key Patent Protected Products
ZELIRA CATALYST FOR GROWTH Advancing Clinical Validation of Key Patent For personal use only Protected Products FDA clinical trials will be an important next step for two key patent protected products: • HOPE®1: Via the establishment of the HOPE® SPV, Zelira has successfully gained the resources to
Slide 15: Corporate Snapshot
Corporate Snapshot For personal use only Financials (as at 7 November 2023) Share Price (Market Data as at 7 November 2023) AUD$ Share Price $0.99 52 week range $0.90 -$ 3.05 Market Capitalisation $11.2M Cash (at 30 Sept 2023) $1.0M Capital Structure (Fully Diluted2) Structure Major Shareholders Dir
Slide 16: Global Board of Directors
Global Board of Directors For personal use only USA GLOBAL USA AUS AUS Osagie Imasogie Dr. Oludare Odumosu Dr Donna Gentile O’Donnell Tim Slate Greg Blake Chairman Global CEO Non-Executive Director Non-Executive Director Executive Director • Over 30 years in the field • Post-clinical development • S
Slide 17: Thank You
For personal use only Thank You Zelira Therapeutics Phone +1 484 630 0650 Email info@zeliratx.com zeliratx.com
Zelira Therapeutics — Shareholder Meeting (November 2023) on 6ix